Endocyte Inc., 3000 Kent Ave., Suite A1-100, West Lafayette 47906, is a biopharmaceutical company developing therapies for the treatment of cancer and other serious diseases. In the first nine months of 2016, Endocyte lost $32.82 million, or 78 cents per share, on revenue of $58,000. In the same period a year earlier, the company lost $31.48 million, or 75 cents per share, on revenue of $58,000. The stock trades on Nasdaq under the ticker EYCT. Information for Proxy Corner was taken from Yahoo! Finance and from the company’s proxy statement dated March 23, 2016. View full Proxy Corner feature.
Please enable JavaScript to view this content.